Hamza Hashmi, Myeloma and Cellular Therapy Physician at Memorial Sloan Kettering Cancer Center, shared a post by Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington on X, adding:
“CAR‑T and bispecifics both deliver deep, durable responses – the real balance point is matching the right therapy to the right patient. True equipoise lives in the nuance of toxicity, logistics, and long‑term immune recovery.”
Quoting Rahul Banerjee‘s post:
“Thanks Blood Journals Portfolio for this Point-Counterpoint with Murali Janakiram. Open access!
How do we decide on cilta-cel vs bsAbs at first relapse in myeloma?
My abbreviated arguments in favor of CAR-T:
CAR-T works very well in CD38-refractory dz (see RW data from Hamza Hashmi et al, or as-treated CARTITUDE-4)
Long-term QOL advantage, with long-term time tox with CAR-T vs bsAbs ± dara + continuous IVIG.
PFS2 of CAR-T to bsAbs likely will still beat bsAbs to CAR-T sequencing-wise unless bsAbs are time-limited
Of course decision-making needs to be individualized!”
Other articles about Myeloma on OncoDaily.